


5




AMENDED SHEET: 495 P.006

carboxamido group, and R_3 or R_4 are equal or different lower alkyl groups C_1 to C_4 ,

the release system being a liposome, a micelle, a nanoparticle, a phospholipidic complex or a supramolecular phospholipidic structure able to incorporate a compound of general structure I in stable and reversible form.

2. A preparation according to claim 1, in form of multilamellar liposomes, composed of phosphatidyl glycerol (PG), phosphatidyl choline (PC) and cholesterol (C) containing an entrapped lexitropsin of formula I in an amount comprised in the range 1-10 percent of the mass of the liposome.
3. A preparation according to claim 1, in form of phospholipidic vesicles composed by polyethyleneglycol ethanolamine (PEGPE), PG and partially hydrogenated egg phosphatidyl choline (PHEPC) containing 1-10 % by weight of a lexitropsin.
4. A preparation according to any one of claims 1-3, comprising distamycin (II) in the form of an organic or inorganic salt, preferably as the hydrochloride, as the active ingredient.




II

20

5. A preparation, according to any one of claims 1-3 comprising a compound X in the form of an organic or inorganic salt, preferably as the hydrochloride.

Best Available Copy



X

6. A topical preparation according to any one of claims 1-5, containing from 0.1 to 10% of active principle.
- 5 7. An injectable preparation according to any one of claims 1-5 providing a dosage from 0.1 to 20 mg of a lexitropsin of general formula I, II or X per kg body weight.
8. The use of the preparations of claims 1-7 for the preparation of medicaments for the treatment of viral, or bacterial, or protozoarian
- 10 infections.

Best Available Copy